FTC
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
【重磅消息】欧盟委员会无条件批准了Novo Holdings对Catalent的165亿美元收购计划
药时代将持续跟踪报道这一重要交易的进展，欢迎广大朋友们关注药时代，获取最新资讯！
